Moderna (MRNA) is back in focus after completing a clinical study of multiple mRNA vaccines targeting several respiratory ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

Moderna (MRNA) closed the most recent trading day at $52.56, moving -1.55% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.61% for the day.

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

Moderna Inc. agreed to pay $950 million to settle litigation related to the delivery technology behind its Covid shot, ...

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores ...